NVAX: Novavax, Inc. Company Profile & Statistics

About

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

Info & Links

CEO

John C. Jacobs

Headquarters

700 Quince Orchard Road
GAITHERSBURG, MD 20878, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

177

Employees

1,543

Novavax, Inc. Statistics

Valuation Measures

Market Capitalization²

1.37B

Enterprise Value

1.02B

Enterprise Value/EBITDA(ttm)

-4.01

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.57

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.22%

Operating Margin(ttm)

-32.18%

Profit Margin(ttm)

-80.72%

Return on Equity(ttm)

Return on Invested Capital(ttm)

21.04%

Return on Assets(ttm)

-17.05%

Income Statement

Revenue(ttm)

885.19M

Revenue Per Share(ttm)

5.53

Gross Profit(ttm)

564.15M

EBITDA(ttm)³

-254.65M

Net Income Available to Common(ttm)

-284.86M

Diluted EPS(ttm)

-2.26

Share Statistics

Beta (5Y Monthly)

2.02

52-Week Change

48.87%

S&P 500 52-Week Change

26.03%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

160.19M

Dividend Yield

0.00%

Float⁴

158.58M

% Held by Insiders

1.00%

% Held by Institutions

53.04%

Balance Sheet

Total Cash(mrq)

920.08M

Total Cash Per Share(mrq)

5.74

Total Debt(mrq)

233.31M

Total Debt/Equity(mrq)

-44.32%

Current Ratio(mrq)

0.93%

Quick Ratio(mrq)

0.93%

Book Value Per Share(mrq)

-3.29

Cash Flow

Operating Cash Flow Per Share(ytd)

0.54

Free Cash Flow(ytd)

74.78M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

NVAX

Novavax, Inc.

Novavax, Inc. Profile